EU MDR – Proposal for Extension of Transition Period
The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

The Covid-19 pandemic, the shortages of raw materials caused by the Russian invasion of Ukraine and the low notified body capacity has put a strain on market readiness. It is expected the number of MDR certificates to be approximately 7,000 by May 2024, which is significatively lower than the 22,793 valid certificates issued under the Directives that will expire in that date.

Thus, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council back on June 2022, some Health Ministers expressed their concerns that the implementation of the MDR could threaten the availability of certain medical devices and jeopardise the access of innovative technologies to the EU market. The Ministers called on the Medical Device Coordination Group (MDCG) to propose solutions for the insufficient capacity of notified bodies and the low level of preparedness of manufacturers. The MDCG published the document MDCG 2022-14 on August 2022, laying out 19 actions to enhancing notified body capacity, access to notified bodies and manufacturers’ preparedness.

Despite their full support for the MDCG position paper 2022-14, several Member States, some Members of the European Parliament and stakeholders consider that those actions will not be sufficient and are calling for additional measures, namely an urgent, targeted legislative initiative to amend the MDR.

The European Commission has listened to the concerns and showed ready to act, presenting a proposal with solutions to the EPSCO Council on 9 December 2022.

The presented elements of a legislative proposal for an amendment of the MDR and IVDR include:

  • An extension of the transitional period [MDR Article 120(3)] with deadlines depending on the risk class of the device. Those deadlines could be 2027 for high-risk devices (class III and class IIb) and 2028 for low-risk devices (class IIa and class I);
  • The extension of the transitional period could be combined with an extension of the validity of certificates issued under the Directives;
  • Conditions to ensure that the extension applies only to devices that do not present unacceptable risks to health and safety, and that not undergone significant changes in design or intended purpose, and for which the manufacturers have already undertaken the necessary steps to launch the certification process under the MDR. These steps include an adaptation of their quality management system to the MDR and submission and/or acceptance of the manufacturer’s application for conformity assessment by a notified body before a certain deadline (e.g. 26 May 2024);
  • The removal of the ‘sell off’ provision [MDR Article 120(4) and IVDR Article 110(4)].

The specific legislative changes have not yet been announced. The extension of validity of certificates issued under the Directives, and if the proposed changes will affect in vitro diagnostic medical devices is still unclear.

The Commission will update the text and provide an MDCG position paper on the expiring of certificates. The legislative process to change the text is expected to begin in early 2023.

The topics for EPSCO Council on 9 December 2022 can be found here!

The recording of the meeting can be found here!

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »